Views: 1,204 | Downloads:
27
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Immune Response of Intradermal Hepatitis B Vaccination at Lower Dose versus Intramuscular Vaccination at Double Standard Dose in Predialytic Chronic Renal Failure Patients
Somboonsilp W 
,
EiamOng S ,
Tungsanga K ,
Tirawatanapong T
,
EiamOng S ,
Tungsanga K ,
Tirawatanapong T The immune responses to hepatitis B vaccine were studied in 2 groups of predialytic chronic
renal failure patients who had negative results of hepatitis B surface antigen (HBsAg), hepatitis B sur-
face antibody (anti-HBs) and hepatitis B core antibody (anti HBc). In the intradermal group, vaccine at
the dose of 0.1 ml, 2 J..lg, was intradermally administered at 5 positions. In the intramuscular group, the
vaccine at the dose of 1.0 ml, 20 J..lg, was intramuscularly given at 2 positions and, thus, was a double
standard dose. Both groups received 4 vaccinations at month 0, 1, 2, and 6 (MO, Ml, M2, and M6).
The results showed that there were no significant differences in the results of seroconversion rates,
defined as having anti HBs levels above 10 miU/ml, between the intradermal (ID) and intramuscular
(IM) groups at Ml, M2, M6, and M7. In patients with positive seroconversion results at M7, the num-
bers of patients in the good and excellent subgroups, having HBs Ab levels ranged 10-999 and above
1,000 miU/ml respectively, showed no difference between both routes. The body weight and serocon-
version rates at M2 and M6 were the factors which had a positive influence on the seroconversion rates
of intradermal hepatitis B vaccination. In conclusion, intradermal hepatitis B vaccination at a lower
dose could provide comparable satisfactory immune response with the intramuscular route at double
the standard dose.
Key word : Hepatitis B Vaccination, Intradermal Route, Intramuscular Route
renal failure patients who had negative results of hepatitis B surface antigen (HBsAg), hepatitis B sur-
face antibody (anti-HBs) and hepatitis B core antibody (anti HBc). In the intradermal group, vaccine at
the dose of 0.1 ml, 2 J..lg, was intradermally administered at 5 positions. In the intramuscular group, the
vaccine at the dose of 1.0 ml, 20 J..lg, was intramuscularly given at 2 positions and, thus, was a double
standard dose. Both groups received 4 vaccinations at month 0, 1, 2, and 6 (MO, Ml, M2, and M6).
The results showed that there were no significant differences in the results of seroconversion rates,
defined as having anti HBs levels above 10 miU/ml, between the intradermal (ID) and intramuscular
(IM) groups at Ml, M2, M6, and M7. In patients with positive seroconversion results at M7, the num-
bers of patients in the good and excellent subgroups, having HBs Ab levels ranged 10-999 and above
1,000 miU/ml respectively, showed no difference between both routes. The body weight and serocon-
version rates at M2 and M6 were the factors which had a positive influence on the seroconversion rates
of intradermal hepatitis B vaccination. In conclusion, intradermal hepatitis B vaccination at a lower
dose could provide comparable satisfactory immune response with the intramuscular route at double
the standard dose.
Key word : Hepatitis B Vaccination, Intradermal Route, Intramuscular Route
Download:
PDF